Etcembly
A British startup developing the next generation of immunotherapies with a pipeline of best-in-class T cell receptor (TCR) therapeutics designed using generative AI.
In August 2023, Etcembly came out of stealth. The company’s lead therapeutic programme, ETC-101, is the world’s first AI-designed bispecific T cell engager. It targets PRAME, a validated antigen present in many cancers.
Latest Etcembly News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze